Shire plc Director/PDMR Shareholding

 
TIDMSHP 
 
Director/PDMR Shareholding 
 
February 21, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) 
 
Notification of transactions by person discharging managerial responsibilities 
 
1.   Details of the person discharging managerial responsibilities 
     ("PDMR") / person closely associated them ("PCA") 
 
a)   Name              Perry Sternberg 
 
2.   Reason for the notification 
 
a)   Position / status Head of US Commercial - PDMR 
 
b)   Initial           Initial notification 
     notification / 
     amendment 
 
3.   Details of the issuer, emission allowance participant, auction 
     platform, auctioneer or auction monitor 
 
a)   Name              Shire plc 
 
b)   LEI               54930005LQRLI2UXRQ59 
 
4.   Details of the transaction(s): section to be repeated for (i) each 
     type of instrument; (ii) each type of transaction; (iii) each date; 
     and (iv) each place where transactions have been conducted 
 
a)   Description of    Shire plc American Depositary Shares ("ADSs") 
     the financial 
     instrument, type 
     of instrument 
 
     Identification    ISIN: US82481R1068 
     code 
 
b)   Nature of the     Exercise of Stock Appreciation Rights ("SARs") in 
     transaction       respect of 3,558 notional ADSs awarded under the 
                       Shire Portfolio Share Plan and consequent receipt 
                       of ADSs. (Details of related disposals of ADSs are 
                       referenced in the sections below.) 
 
c)   Price(s) and          Exercise price(s)      Volume(s) ADSs received 
     volume(s) 
                                $119.27                    1,202 
 
d)   Aggregated        N/A (single transaction) 
     information 
 
e)   Date of the       February 17, 2017 
     transaction 
 
f)   Place of the      N/A 
     transaction 
 
5.   Details of the transaction(s): section to be repeated for (i) each 
     type of instrument; (ii) each type of transaction; (iii) each date; 
     and (iv) each place where transactions have been conducted 
 
a)   Description of    Shire plc American Depositary Shares ("ADSs") 
     the financial 
     instrument, type 
     of instrument 
 
     Identification    ISIN: US82481R1068 
     code 
 
b)   Nature of the     Disposals of ADSs 
     transaction       (Disposals marked with * are in relation to the 
                       exercise of SARs referenced in section 4. above. 
                       Part of the proceeds of these disposals were used 
                       to satisfy personal tax liabilities arising from 
                       the exercise of the SARs.) 
 
c)   Price(s) and              Price(s)                  Volume(s) 
     volume(s) 
                               $180.87*                     200 
 
                               $180.73*                     200 
 
                               $180.73*                     200 
 
                                $180.28                     99 
 
                                $180.29                     300 
 
d)   Aggregated         Weighted average price            Volume 
     information 
                               $180.58                     999 
 
e)   Date of the       February 17, 2017 
     transaction 
 
f)   Place of the      NYSE (BQT) 
     transaction 
 
6.   Details of the transaction(s): section to be repeated for (i) each 
     type of instrument; (ii) each type of transaction; (iii) each date; 
     and (iv) each place where transactions have been conducted 
 
a)   Description of    Shire plc American Depositary Shares ("ADSs") 
     the financial 
     instrument, type 
     of instrument 
 
     Identification    ISIN: US82481R1068 
     code 
 
b)   Nature of the     Disposals of ADSs in relation to the exercise of 
     transaction       SARs referenced in section 4. above. Part of the 
                       proceeds of these disposals were used to satisfy 
                       personal tax liabilities arising from the exercise 
                       of the SARs. 
 
c)   Price(s) and              Price(s)                  Volume(s) 
     volume(s) 
                                $180.86                     100 
 
                                $180.85                     100 
 
                                $180.85                     185 
 
                                $180.85                     100 
 
                                $180.71                     17 
 
d)   Aggregated         Weighted average price            Volume 
     information 
                                $180.85                     502 
 
e)   Date of the       February 17, 2017 
     transaction 
 
f)   Place of the      NASDAQ 
     transaction 
 
7.   Details of the transaction(s): section to be repeated for (i) each 
     type of instrument; (ii) each type of transaction; (iii) each date; 
     and (iv) each place where transactions have been conducted 
 
a)   Description of    Shire plc American Depositary Shares ("ADSs") 
     the financial 
     instrument, type 
     of instrument 
 
     Identification    ISIN: US82481R1068 
     code 
 
b)   Nature of the     Disposal of ADSs in relation to the exercise of 
     transaction       SARs referenced in section 4. above. Part of the 
                       proceeds of this disposal were used to satisfy 
                       personal tax liabilities arising from the exercise 
                       of the SARs. 
 
c)   Price(s) and              Price(s)                  Volume(s) 
     volume(s) 
                                $180.76                     100 
 
d)   Aggregated        N/A (single transaction) 
     information 
 
e)   Date of the       February 17, 2017 
     transaction 
 
f)   Place of the      Bats BYX 
     transaction 
 
 
Oliver Strawbridge 
 
Senior Assistant Company Secretary 
 
For further information please contact: 
 
Investor Relations 
 
Ian Karp                        [e-mail]            [phone] 
 
Robert Coates                   [e-mail]          [phone] 
 
Media 
 
Lisa Adler                      [e-mail]       [phone] 
 
Debbi Ford                      [e-mail]       [phone] 
 
NOTES TO EDITORS 
 
About Shire 
 
Shire is the leading global biotechnology company focused on serving people 
with rare diseases. We strive to develop best-in-class products, many of which 
are available in more than 100 countries, across core therapeutic areas 
including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage 
Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary 
Angioedema; and a growing franchise in Oncology. 
 
Our employees come to work every day with a shared mission: to develop and 
deliver breakthrough therapies for the hundreds of millions of people in the 
world affected by rare diseases and other high-need conditions, and who lack 
effective therapies to live their lives to the fullest. 
 
www.shire.com 
 
 
 
END 
 

(END) Dow Jones Newswires

February 21, 2017 09:33 ET (14:33 GMT)